Reaction

Chronic Lymphocytic Leukaemia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,706 reports · 79 co-occurring drugs

As of the last recalculation, Chronic Lymphocytic Leukaemia appears in 4,706 FAERS reports alongside 79 co-occurring drug terms. The strongest observed disproportionality signal is VENETOCLAX (PRR 65.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Venetoclax	770	65.9	66.8
Ibrutinib	901	60.8	61.5
Bendamustine Hcl	150	44.2	44.6
Bendamustine Hydrochloride	108	40.8	41.2
Obinutuzumab	111	30.5	30.7
Fludarabine Phosphate	244	28.9	29.1
Acalabrutinib	74	27.4	27.6
Romiplostim	75	22.4	22.5
Rituximab	679	16.4	16.5
Alemtuzumab	64	14.8	14.9
Human Immunoglobulin G	47	10.2	10.2
Eltrombopag Olamine	42	8.1	8.1
Allopurinol	271	8.1	8.1
Cyclophosphamide Injection, Solution	283	7.5	7.5
Cyclophosphamide	283	7.5	7.5
Cyclophosphamide For Injection	283	7.5	7.5
Valacyclovir	61	6.5	6.5
Cladribine	13	6.0	6.0
Sulfamethoxazole And Trimethoprim	111	5.9	5.9
Valacyclovir Hydrochloride	93	5.9	5.9
Vincristine Sulfate	39	5.9	5.9
Busulfan	21	5.9	5.9
Ofatumumab	44	5.9	5.9
Filgrastim	48	5.7	5.7
Acyclovir	143	5.7	5.7
Doxorubicin	102	5.2	5.2
Bleomycin Sulfate	12	5.1	5.2
Atovaquone	9	5.0	5.0
Rosuvastatin Calcium	31	4.9	4.9
Febuxostat Tablets 40 Mg	11	4.8	4.8
Febuxostat Tablets 80 Mg	11	4.8	4.8
Simvastatin	254	4.7	4.7
Doxorubicin Hydrochloride	33	4.5	4.5
Erythropoietin	19	4.1	4.1
Daspone	9	4.1	4.1
Dapsone Gel, 5%	9	4.1	4.1
Febuxostat	15	4.0	4.0
Dapsone	9	3.7	3.7
Polyethylene Glycol	9	3.7	3.7
Deferasirox	22	3.7	3.7
Fluconazole	57	3.6	3.6
Imatinib	14	3.5	3.5
Itraconazole	9	3.4	3.4
Epoetin Alfa	9	3.4	3.4
Ifosfamide	16	3.3	3.3
Posaconazole	12	3.3	3.3
Baricitinib	7	3.2	3.2
Voriconazole	22	3.2	3.2
Diphenhydramine Hcl	8	3.2	3.2
Voriconazole Injection	14	2.9	2.9
Posaconazole Delayed-Release	7	2.8	2.8
Meropenem	20	2.8	2.8
Gemcitabine	24	2.7	2.7
Etoposide	44	2.7	2.7
Entecavir	7	2.7	2.7
Clozapine	73	2.6	2.6
Azacitidine For	10	2.4	2.4
Gemcitabine Hydrochloride	29	2.4	2.4
Amlodipine Besylate And Valsartan	6	2.4	2.4
Rasagiline Mesylate	6	2.4	2.4
Ranitidine Hydrochloride	29	2.4	2.4
Lenalidomide	220	2.4	2.4
Natalizumab	91	2.2	2.2
Imatinib Mesylate	13	2.1	2.1
Azacitidine	13	1.9	1.9
Pegfilgrastim	43	1.9	1.9
Ruxolitinib	31	1.9	1.9
Interferon Beta-1A	78	1.8	1.8
Sofosbuvir	8	1.8	1.8
Cisplatin	31	1.8	1.8
Blinatumomab	4	1.7	1.7
Bosutinib	3	1.5	1.5
Vemurafenib	4	1.5	1.5
Nivolumab	32	1.5	1.5
Daptomycin	3	1.4	1.4
Glatiramer Acetate	19	1.4	1.4
Peginterferon Beta-1A	3	1.0	1.0
Osimertinib	6	0.8	0.8
Guselkumab	5	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.